MDxHealth (FRA:O6C1) Cyclically Adjusted Revenue per Share: €1.73 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O6C1 MDxHealth SA FRA:O6C1
48 GF Score
Price €0.42
GF Value €1.12
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MDxHealth Cyclically Adjusted Revenue per Share?

MDxHealth FRA:O6C1 +288.89% 48 Cyclically Adjusted Revenue per Share is €1.73 as of Mar. 2026. GuruFocus rates FRA:O6C1 with a GF Score™ of 48/100 and a GF Value™ of €1.12 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

MDxHealth's adjusted revenue per share for the three months ended in Mar. 2026 was €0.454. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.73 for the trailing ten years ended in Mar. 2026.

During the past 12 months, MDxHealth's average Cyclically Adjusted Revenue Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-15), MDxHealth's current stock price is €0.42. MDxHealth's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €1.73. MDxHealth's Cyclically Adjusted PS Ratio of today is 0.24.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MDxHealth was 1.98. The lowest was 0.16. And the median was 0.91.


MDxHealth  (FRA:O6C1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

MDxHealth's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.42/1.73
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MDxHealth was 1.98. The lowest was 0.16. And the median was 0.91.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


MDxHealth Cyclically Adjusted Revenue per Share Related Terms


MDxHealth Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for MDxHealth's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MDxHealth Cyclically Adjusted Revenue per Share Chart

MDxHealth Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.30 1.72

MDxHealth Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.50 3.48 1.90 1.72 1.73

FRA:O6C1 vs AWHL, QUCY, BIOQ: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, MDxHealth's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MDxHealth Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MDxHealth's Cyclically Adjusted PS Ratio falls into.


FRA:O6C1
48GF Score
MDxHealth SA FRA:O6C1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MDxHealth Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MDxHealth's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.454/136.5600*136.5600
=0.454

Current CPI (Mar. 2026) = 136.5600.

MDxHealth Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201106 0.000 95.508 0.000
201112 0.000 96.360 0.000
201206 0.000 97.659 0.000
201212 0.000 98.511 0.000
201306 0.000 99.215 0.000
201312 0.000 99.462 0.000
201406 0.000 99.482 0.000
201412 0.000 99.086 0.000
201506 0.000 100.107 0.000
201512 0.000 100.572 0.000
201606 0.000 102.267 0.000
201612 0.000 102.614 0.000
201706 0.000 103.902 0.000
201712 0.000 104.804 0.000
201806 0.000 106.063 0.000
201812 0.000 107.252 0.000
201906 0.000 107.896 0.000
201912 0.000 108.065 0.000
202006 0.000 108.540 0.000
202012 0.000 108.511 0.000
202106 0.000 110.305 0.000
202109 0.368 111.543 0.451
202112 0.383 114.705 0.456
202203 0.335 118.620 0.386
202206 0.479 120.948 0.541
202209 0.667 124.120 0.734
202212 0.758 126.578 0.818
202303 0.621 126.528 0.670
202306 0.573 125.973 0.621
202309 0.668 127.083 0.718
202312 0.655 128.292 0.697
202403 0.665 130.552 0.696
202406 0.750 130.691 0.784
202409 0.444 130.968 0.463
202412 0.477 132.346 0.492
202503 0.464 134.348 0.472
202506 0.443 133.495 0.453
202509 0.467 133.740 0.477
202512 0.482 135.070 0.487
202603 0.454 136.560 0.454

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.73 mean?
MDxHealth (FRA:O6C1) has a Cyclically Adjusted Revenue per Share of €1.73 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MDxHealth and its competitors.
Is MDxHealth's Cyclically Adjusted Revenue per Share too high?
MDxHealth's current Cyclically Adjusted Revenue per Share is €1.73. Overall, MDxHealth has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's Cyclically Adjusted Revenue per Share compare to AWHL and QUCY?
MDxHealth's Cyclically Adjusted Revenue per Share of €1.73 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MDxHealth and its competitors. MDxHealth's current Cyclically Adjusted Revenue per Share is €1.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (FRA:O6C1) is currently considered Possible Value Trap. The stock's GF Value™ is €1.12, compared to a current price of €0.42 — trading 62.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.73. MDxHealth's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For MDxHealth (FRA:O6C1), the current Cyclically Adjusted Revenue per Share is €1.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MDxHealth (FRA:O6C1) Overvalued in 2026?

Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued. The current stock price of €0.42 is trading 62.5% below its estimated GF Value™ of €1.12. GuruFocus considers MDxHealth to be Possible Value Trap.

Key valuation signals for FRA:O6C1:

  • Cyclically Adjusted Revenue per Share: €1.73
  • GF Value™: €1.12 vs. price of €0.42 (62.5% below fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the FRA:O6C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MDxHealth Business Description

Other Exchanges MDXH:USA
Address Zone Industrielle des Hauts-Sarts, Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
48GF Score

Get the complete analysis for FRA:O6C1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price
€1.12
GF Value